EpimAb: Yet Another Chinese Immuno-oncology Darling of Capital Market
EpimAb Biotherapeutics undertook its Series B funding round of USD 74 million.
On 5 June 2019, A Series B funding round of USD 74 million has pushed up EpimAb’s total amount of fundraisings to over USD 100 million. SDIC Fund and Sherpa Healthcare Partner led this round.
Shanghai-based EpimAb Biotherapeutics is a privately owned biopharmaceutical company focused on creating a pipeline of bispecific antibody therapeutics centred around immuno-oncology.
Bispecific antibody therapeutic is a brand new and innovative method of immunotherapy and EpimAb claims to be a vanguard in this sector.
Currently, the primary therapies used in immunotherapy include immunological checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. The bispecific antibody is a novel approach and has yet to be tested comprehensively.
What's more, the company's product is still at a pre-clinical stage.
Apart from EpimAb, I-Mab Bio (天境生物), Jacobio (加科思), YuceBio (裕策生物) and Shanghai Cell Therapy Group count among the other players in China that are aiming to provide immunotherapy solutions for cancer treatment.
Led by I-Mab Bio, Chinese immunotherapy companies have attracted significant investor attention due to the overall industrial atmosphere and favorable regulatory environment in 2019.